GargSK, WeinzimerSA, TamborlaneWV, et al.: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
2.
BergenstalRM, GargS, WeinzimerSA, et al.: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316:1407–1408.
3.
SherwinRS, KramerKJ, TobinJD, et al.: A model of the kinetics of insulin in man. J Clin Invest, 1974; 53:1481–1492.
4.
BergmanRN, PhillipsLS, CobelliC: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest, 1981; 68:1456–1467.
5.
KanderianSS, WeinzimerS, VoskanyanG, SteilGM: Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes. J Diabetes Sci Technol, 2009; 3:1047–1057.
6.
KanderianSS, WeinzimerSA, SteilGM: The identifiable virtual patient model: comparison of simulation and clinical closed-loop study results. J Diabetes Sci Technol, 2012; 6:371–379.
7.
SteilGM, RebrinK, DarwinC, et al.: Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes, 2006; 55:3344–3350.
8.
SteilGM, PalermCC, KurtzN, et al.: The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab, 2011; 96:1402–1408.
9.
LoutseikoM, VoskanyanG, KeenanDB, SteilGM: Closed-loop insulin delivery utilizing pole placement to compensate for delays in subcutaneous insulin delivery. J Diabetes Sci Technol, 2011; 5:1342–1351.
10.
SteilGM, RebrinK, JanowskiR, et al.: Modeling beta-cell insulin secretion—implications for closed-loop glucose homeostasis. Diabetes Technol Ther, 2003; 5:953–964.
11.
SteilGM, GrodskyGM: The artificial pancreas: is it important to understand how the beta cell controls blood glucose?. J Diabetes Sci Technol, 2013; 7:1359–1369.
12.
SteilGM, ClarkB, KanderianS, RebrinK: Modeling insulin action for development of a closed-loop artificial pancreas. Diabetes Technol Ther, 2005; 7:94–108.
13.
SteilGM, ReifmanJ: Mathematical modeling research to support the development of automated insulin-delivery systems. J Diabetes Sci Technol, 2009; 3:388–395.
14.
SteilGM, HipszerB, ReifmanJ: Update on mathematical modeling research to support the development of automated insulin delivery systems. J Diabetes Sci Technol, 2010; 4:759–769.
15.
KovatchevBP, BretonM, Dalla ManC, CobelliC: In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol, 2009; 3:44–55.
16.
PatekSD, BretonMD, ChenY, et al.: Linear quadratic gaussian-based closed-loop control of type 1 diabetes. J Diabetes Sci Technol, 2007; 1:834–841.
17.
CameronF, BequetteBW, WilsonDM, et al.: A closed-loop artificial pancreas based on risk management. J Diabetes Sci Technol, 2011; 5:368–379.
18.
MagniL, RaimondoDM, BossiL, et al.: Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol, 2007; 1:804–812.
19.
LaxminarayanS, ReifmanJ, SteilGM: Use of a food and drug administration-approved type 1 diabetes mellitus simulator to evaluate and optimize a proportional-integral-derivative controller. J Diabetes Sci Technol, 2012; 6:1401–1412.
20.
RuizJL, SherrJL, CengizE, et al.: Effect of insulin feedback on closed-loop glucose control: a crossover study. J Diabetes Sci Technol, 2012; 6:1123–1130.
21.
PanteleonAE, LoutseikoM, SteilGM, RebrinK: Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes, 2006; 55:1995–2000.
22.
Dalla ManC, MichelettoF, LvD, et al.: The UVA/PADOVA type 1 diabetes simulator: new features. J Diabetes Sci Technol, 2014; 8:26–34.
23.
PinskerJE, LeeJB, DassauE, et al.: Randomized crossover comparison of personalized MPC and PID control algorithms for the artificial pancreas. Diabetes Care, 2016; 39:1135–1142.
24.
WolpertH, KavanaghM, Atakov-CastilloA, SteilGM: The artificial pancreas: evaluating risk of hypoglycaemia following errors that can be expected with prolonged at-home use. Diabet Med, 2016; 33:235–242.
